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Background
Approximately 20% of children with attention-deficit hyper-
activity disorder (ADHD) experience clinical levels of impairment
into adulthood. In the UK, there is a sharp reduction in ADHDdrug
prescribing over the period of transition from child to adult ser-
vices, which is higher than expected given estimates of ADHD
persistence, and may be linked to difficulties in accessing adult
services. Little is currently known about geographical variations
in prescribing and how this may relate to service access.
Aims
To analyse geographic variations in primary care prescribing of
ADHD medications over the transition period (age 16–19 years)
and adult mental health service (AMHS) referrals, and illustrate
their relationship with UK adult ADHD service locations.
Method
Using a Clinical Practice Research Datalink cohort of people with
an ADHD diagnosis aged 10–20 in 2005 (study period 2005–2013;
n = 9390, 99% diagnosed <18 years), regional data on ADHD
prescribing over the transition period and AMHS referrals, were
mapped against adult ADHD services identified in a linked
mapping study.
Results
Differences were found by region in themean age at cessation of
ADHD prescribing, range 15.8–17.4 years (P<0.001), as well as in
referral rates to AMHSs, range 4–21% (P<0.001). There was no
obvious relationship between service provision and prescribing
variation.
Conclusions
Clear regional differenceswere found in primary care prescribing
over the transition period and in referrals to AMHSs. Taken
together with service mapping, this suggests inequitable provi-
sion and is important information for those who commission and
deliver services for adults with ADHD.
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Background
Rates of primary care prescribing of attention-deficit hyperactivity
disorder (ADHD) medication for young people with ADHD in
the UK appear to decline more steeply than expected given the
rate of symptom reduction from follow-up studies.1 The timing
coincides with the age at which children’s services end, usually
between 16 and 18, and transition into adult services occurs if con-
tinuation of medication is recommended. This is a key developmen-
tal stage when multiple other transitions are likely, such as changing
educational setting or leaving home for the first time. The National
Institute for Health and Care Excellence (NICE) guidelines recom-
mend that prescribing of ADHD medication for adults should
happen via shared-care agreements between primary and secondary
care.2 The principle of shared care assumes that the young person
will be in the care of an adult mental health service (AMHS) with
the general practitioner (GP) continuing to prescribe.3 However,
problems could arise, because of the lack of adult ADHD services,
because there is no shared-care agreement or because GPs are not
prepared, trained or supported to prescribe.4,5
Evidence is increasingly emerging of low rates of successful
transition and poor-quality transition experiences for people with
ADHD.6,7 Disruption of care during transition adversely affects
young people with mental health conditions8 whereas untreated
ADHD can worsen health, education and occupational out-
comes.9,10 For those young people who continue to require medica-
tion, cessation of prescribing could be related to lack of service
provision. Studies have suggested that there are gaps in provision
of adult ADHD services and a shortage of specialist services.11,12
Population prescribing studies suggest higher incidences of
ADHD diagnosis and prescribing in young people in areas of socio-
economic deprivation,13 however, this is unsurprising given the
strong link between deprivation and the prevalence of ADHD.14
Aims
To our knowledge, no study has examined regional differences in
prescribing for young people with ADHD in the UK during the
transition period. Knowledge and understanding of any regional
variations in prescribing rates through the transition, and potential
links to availability of dedicated adult ADHD services may allow
commissioners and practitioners to address inequalities of provi-
sion. The current study aimed to analyse regional variation in pre-
scribing patterns of ADHD medication and rates of referrals into
AMHSs for young people with ADHD aged between 16 and 20
from 2005 to 2013, using the Clinical Practice Research Datalink
(CPRD). It also aims to explore relationships between prescribing
patterns, referral rates and service locations.
Method
Data source
The CPRD is a large database of anonymised patient records
including diagnoses, prescribed drugs and referrals to secondary
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care services. The primary care section is contributed to by over 670
GP practices across the UK and contains the records of over 11
million patients. It covers up to 6% of the UK population and is
broadly representative in terms of age, gender, ethnicity and geo-
graphical location of practices.15
The data source for service locations was the 2018 UK mapping
study, a national survey of adult ADHD services, run as part of the
‘Children and Adolescents with Attention Deficit Hyperactivity
Disorder (ADHD) in Transition from Child to Adult services’
(CATCh-uS) study of transition in ADHD.16 Data on services
were gathered from over 2600 informants from across the UK;
patients, health workers and National Health Service (NHS) com-
missioners. Data were collected via an online survey, freedom of
information requests to commissioners (90% response rate) and
surveillance reports. A total of 44 NHS dedicated adult ADHD ser-
vices were identified, consisting of 29 ADHD; 7 ADHD and autism
spectrum disorder; and 8 neurodevelopmental services.17
Study design and population
We used a cohort from the CPRD of young people aged between 10
and 20 in 2005, for the study period that ran from 1 Jan 2005 until 31
Dec 2013.1 This allowed us to study prescribing over the transition
period (see Statistical analysis below). To be included, individuals
had to have a diagnosis of ADHD coded in their primary care
record (n = 9390). Of included patients, 98.6% (n = 9261) had
their first ADHD clinical code coded under the age of 18. ADHD
diagnoses were defined as any of the 22 CPRD medical codes and
primary care Read terms (based on ICD-10 F90 or DSM categories)
that relate to an ADHD diagnosis (see Newlove-Delgado et al1 for
details on patient identification and supplementary material).
Patients were defined as having an ADHD prescription if any pre-
scription record had an ADHD-related medication code, including
categories of stimulants and non-stimulants for ADHD.1 Rare cases
of patients with narcolepsy, for which ADHD medication may be
prescribed (n<20) were excluded from the analysis.
Regions were defined by the NHS strategic health authority
(SHA) boundaries, in which reporting GP practices were situated
during the study period.
Statistical analysis
The first phase of analysis used Stata version 15.018 and focused on
changes in prescribing of ADHDmedication through the transition
period (defined as 16–19 years of age) and incidences of referral to
AMHSs. The CPRD did not supply dates of birth, therefore age
bands were assigned, with, for example, age-band 14/15 indicating
the year of their 15th birthday. We defined this transition period
as being between the year of their 16th birthday, which commonly
marks the end of children’s services, and the year of their 19th birth-
day, which is when the transition to adult services should be com-
pleted, according to NICE guidance.19
First, analyses were carried out to examine differences in pre-
scribing prevalence by region. The proportion of patients with an
ADHD prescription at any point was calculated, followed by the
proportion of others with a prescription in each age band from
14/15 years to 19/20 years, to cover the transition period and
1 year either side. For each region, the difference in the proportion
of patients with an ADHD prescription between the beginning and
end of the transition period was then reported. The denominator for
each age band only included patients who had records for the full
year in question.
Age at cessation of medication by region was then examined,
with cessation defined as a gap of more than 6 months in prescrip-
tions. This was chosen to allow for uncertainty in estimating pre-
scription length as ADHD prescriptions are typically provided for
between a 1- and 2-month duration, and to account for any medi-
cation ‘breaks’ that may occur. When calculating age at cessation,
the cases of patients that were censored, as they still had a prescrip-
tion at the time of leaving the database (i.e. lost to follow-up or at the
age boundary of the cohort) were excluded from the analysis. As full
details of date of birth are not provided by CPRD, to calculate the
age of cessation date of birth was designated as 1 July for each indi-
vidual, minimising error each way to a maximum of 6 months.
Mean age of cessation was calculated with confidence intervals,
and a one-way ANOVA run to explore differences in means by
region.
Patients were defined as having a referral to an AMHS if they
were coded with a referral to adult psychiatry, a community psychi-
atric nurse or clinical psychology. The proportion of patients
referred by region was calculated, examining differences in propor-
tions using the χ2-test. Given that referral might have been for non-
ADHD related treatment, we also described the proportion exclud-
ing the cases of patients potentially referred for a psychiatric
comorbidity. The first definition used was ‘cases without any
other psychiatric diagnoses’. However, as diagnoses are not coded
as reliably as prescription data in the CPRD,20 and common
comorbidities such as autism spectrum disorder are not consistently
treated in AMHSs, a second definition was also used of ‘cases
without a prescription for any other psychotropic medication’.
Linear regression was used to examine the association between
region (independent variable) and the age of cessation (dependent
variable) and subsequently adjusted for referral to an AMHS as a
covariate. The second phase of analysis used a geographic informa-
tion system, QGIS 2.18, to analyse and display the service mapping
data alongside the prescribing data. Shapefiles for UK countries and
SHA regions were imported21 andmaps created to illustrate changes
in patterns of prescribing and rates of referral to AMHSs by region.
Locations of dedicated NHS services for adults, as identified in the
2018 CATCh-uS study17 were plotted on the same maps.
We assert that all procedures contributing to this work comply
with the ethical standards of the relevant national and institutional
committees on human experimentation and with the Helsinki
Declaration of 1975, as revised in 2008. All procedures involving
human patients were approved by the following: for the CPRD
data-set, the Independent Scientific Advisory Committee on
behalf of the National Research Ethics Service Committee (protocol
number 13_213); for the 2018 CATCh-uS mapping study, the
University of Exeter Medical School Ethics Committee (REC
Application Number: 15/07/070).
Results
There were 9390 eligible patients: 84% (n = 7876) were male, 25%
(n = 2335) had a recorded diagnosis of a psychiatric comorbidity,
62% (n = 5780) had at least one recorded prescription for an
ADHD medication, and 25% (n = 2336) had a prescription for
any other (non-ADHD) psychotropic medication. Following cen-
soring, 3476 patients (37%) had complete data that allowed us to
calculate age of cessation of ADHD medication. Patients who
were censored were similar to those that were uncensored with
respect to medication duration and year of birth.
Percentage of patients with ADHD with an ADHD
prescription
Scotland was the region with the highest percentage of patients
(75%) with at least one ADHD prescription at any point, whereas
Yorkshire and the Humber had the lowest (48%). There were
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differences by region in the proportion of patients that had an
ADHD medication prescribed for every age band, see Fig. 1.
Difference in proportion of patients with an ADHD
prescription before and after transition
The drop in the proportion of patients with an ADHD prescription
between the year of their 16th birthday and the year of their 19th
birthday (age bands 15/16 and 18/19) was 19% for all patients;
but varied by region from 6% in the North East to 25% in the
North West, see Table 1 and Fig. 1.
Mean age of cessation of ADHDmedication prescription
The mean age of termination (or interruption) of medication pre-
scription was 16.6 years (s.d. = 2.63, 95% CI 16.5–16.7) (Table 1).
A one-way ANOVA determined that differences in the mean age
of end of ADHD medication prescription were statistically signifi-
cant by region, with mean ages ranging from 15.8 to 17.4 years,
F(12, 3463) = 6.18, P<0.001.
Proportion of patients referred to AMHSs
The percentage of patients with ADHD referred to any AMHS was
11% (Table 1), but varied by region from 4 to 21%, χ2(12, n = 9390) =
121.60, P<0.001. When patients with any other non-ADHD psy-
chiatric diagnosis were excluded from the data-set, the overall pro-
portion dropped to 9%, and varied by region from 3 to 15% (χ2(12,
n = 7055) = 49.12, P<0.001). When patients with a prescription for
any other psychotropic medication were excluded, the percentage
of those referred was even lower (7%), and also varied by region
from 3 to 11% (χ2(12, n = 7052) = 27.73, P>0.001).
There was a marginal association between region and the age of
cessation of ADHD medication prescription in the unadjusted
model (R2 = 0.0013, F(1, 3474) = 4.56, P = 0.03). However,
when referral to any AMHS was added to the model, (R2 = 0.0046,
F(2, 3473) = 83.55, P<001), region was no longer a predictor and
only referral to any AMHS was a significant predictor of age of
prescription cessation.
Regional variations, mapped against service locations
Figures 2 and 3 clearly illustrate the regional variations in prescrib-
ing patterns, referral rates and service locations. On visual inspec-
tion, however, there were no clearly identifiable relationships
between reductions in prescribing, referral rates or identified loca-
tions of dedicated adult ADHD services.
Discussion
We detected regional variations in primary care prescribing of
ADHDmedication for young people with ADHD through the tran-
sition period, and in the proportions of young people with ADHD
being referred to an AMHS. The creation of visual maps showed
clear variation by region for prescribing, referrals and the location
of dedicated services, but no discernible relationships between
these three measures. Distribution of services was patchy and
uneven across the UK and there were many areas without a dedi-
cated service nearby. These findings are novel, providing evidence
of potential inequalities in healthcare provision across the UK for
this patient group, which are likely to have an impact on continu-
ation of care and treatment into adulthood.
Organisation and availability of adult ADHD services
All young people included in this study had a diagnosis of ADHD in
their primary care record; therefore, the findings of significant vari-
ation are unlikely to be because of regionally patterned differences
in prevalence. Variations in prescribing and in referrals found by
region are therefore likely to be related to differences in the organ-
isation and availability of services for ADHD. There is currently no
established or consistent approach to the configuration of health
services for adult ADHD. Management in secondary care may be
undertaken in generic AMHSs or within a specialist service,22 con-
sequently variations found in primary care prescribing through
transition may reflect a mixture of service models. Whether or
not a young person has psychiatric comorbidities can also affect
whether they are eligible for AMHSs, or directed to specialist or
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generic services.23 This may contribute to our findings of differences
in referral rates for individuals without a comorbidity, or other psy-
chotropic medication.
The service mapping we present also demonstrates a patchy
geographical spread of specialist adult ADHD services. NICE
recommends diagnosis and treatment for adults via separate
teams or clinics with expertise in ADHD, but with no guidance
on the size and time commitment.2 The NHS is structured differ-
ently in the four countries that comprise the UK, including different
commissioning arrangements.24 There is an argument that treat-
ment within generic services, which are not identified on the map,
is potentially a cost-effective and practical solution to long-term
Table 1 Difference in attention-deficit hyperactivity disorder (ADHD) prescriptions, mean age of cessation of ADHDmedication, and instances of referral
to adult mental health services (AMHSs); by subgroup and region
Region
Difference in % with ADHD
prescription pre- and post-
transition (15/16–18/19 years)
Age of prescription
cessation, mean
(95% CIs)
Percentage referred to an AMHSs (%)
All
patients
Patients without any
other psychiatric
diagnosis
Patients without prescription
for any other psychotropic
medication
North East 6 17.4 (16.5–18.2) 5 3 3
North West 25 16.6 (16.4–16.9) 11 10 8
Yorkshire & Humber 18 15.8 (15.4–16.3) 8 8 6
East Midlands 18 16.5 (16.1–17.0) 4 3 4
West Midlands 15 16.1 (15.7–16.4) 11 10 8
East of England 20 16.2 (15.9–16.4) 8 7 6
South West 17 16.9 (16.6–17.2) 7 7 6
South Central 22 16.6 (16.3–16.8) 11 9 6
London 15 17.4 (17.0–17.8) 11 8 6
South East Coast 18 16.6 (16.3–16.8) 13 11 9
Northern Ireland 18 15.9 (15.4–16.4) 13 10 8
Scotland 18 16.9 (16.7–17.2) 10 8 7
Wales 20 16.6 (16.3–16.9) 21 15 11
Total 19 16.6 (16.5–16.7) 11 9 7
0–5%
6–10%
11–15%
16–20%
21–25%
Dedicated ADHD
Drop in ADHD
medication
Adult NHS
services
Fig. 2 Drop in prescribing rates for attention-deficit hyperactivity
disorder (ADHD) medication for young people with ADHD, between
the age bands of 15/16 and 18/19: plotted against locations of
dedicated adult ADHD services.
NHS, National Health Service.
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Fig. 3 Referral rates to adult mental health services (AMHSs) for
young people with attention-deficit hyperactivity disorder (ADHD),
plotted against identified locations of dedicated adult ADHD
services.
NHS, National Health Service.
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treatment of ADHD, however, issues need to be addressed, such as a
lack of training of AMHS professionals and the fact that services are
often set up to provide episodic care, rather than to treat long-term
conditions.23
Variation in primary care practice
Our findings on variation in prescribing may also reflect regional
differences in primary care practice and culture to some extent,
however, we were unable to examine variation by clinical commis-
sioning group (see Limitations). Although medication has been
recommended by NICE for management of adult ADHD, as the
2008 guidance evidence suggests GPs may feel unsupported to pre-
scribe ADHD medications to adults, with issues such as lack of
training or lack of available support from a specialist service identi-
fied as barriers to prescribing.4 For example, a study in Northern
Ireland reported reluctance from GPs to prescribe under a
shared-care partnership, which may bear some relation to our
finding that Northern Ireland had the earliest mean age of medica-
tion cessation in our analysis.25
Transitions into adult ADHD services
Regardless of local prescribing and secondary care arrangements, if
a young person does not transition into adult services, they are
unlikely to continue to receive treatment into adulthood. Young
people with ADHD are already at a higher risk of a range of negative
health, educational and occupational outcomes compared with the
general population, and without treatment, these risks are
increased.9,10 The regional differences in prescribing and referrals
found in this study support available qualitative evidence of unsup-
ported transitions and findings of limited adherence to and incon-
sistencies in implementation of the NICE guidelines on
transition.7,11,12
Strengths and limitations
Strengths of this study include a large population-based sample of
primary care records. To our knowledge this is the first time
primary care ADHD medication prescribing in the transition age
group among adults with a childhood diagnosis and referrals to
AMHSs have been analysed by region. It is also the first time
regional quantitative data on primary care prescribing and referral
rates have been explored in comparison with national UK data on
the locations of adult ADHD services. A key limitation of this was
the time lapse between the study period for CPRD data (2005–
2013) and the date of the service mapping study (2018). The provi-
sion and organisation of mental health services are constantly evolv-
ing and some services identified in 2018 may only have been
recently commissioned. In addition, although the CPRD data-set
automatically includes all primary care prescriptions, those issued
through a secondary mental health service may be missing.15
Although we were able to analyse patterns of regional variation,
we had no information on the severity of the ADHD diagnosis for
each patient, and could not determine whether prescribing deci-
sions were clinically appropriate or inappropriate. We were also
unable to adjust for continuing symptom severity over time.
There is considerable evidence emerging from qualitative and quan-
titative research of the premature cessation of ADHD medication
through transition,1,26,27 which taken with evidence of regional var-
iations in prescribing, are indicative of gaps in provision. But it is
also possible that evidence of higher rates of continued prescribing
at age 17/18 in some regionsmight reflect the cases of patients where
a failure to review need had led to an inappropriate continuation of
prescribing.
NICE2 guidance states that once a young person is stable on
ADHD medication, prescribing should be through shared care,
however, in some patients with complex cases secondary services
may have prescribed for longer than the 6-month time period
defined as medication cessation in this study. If this prescribing is
not recorded in CPRD these patients may have been inaccurately
recorded as having stopped medication. In addition, we may have
underestimated referral rates, as although CPRD records referrals
from primary care into AMHSs, if referrals are made using free-
text letters these can only be captured by scanning the free text,
which we did not have access. Similarly, free-text references to refer-
rals between child services and AMHSs would not be included.
However, this limitation is likely to apply across all regions, and is
unlikely to have influenced the significant variation in referral
rates found in our analysis.
A further study weakness is the size of regions analysed.
Although SHA reflected the structure by which healthcare was orga-
nised during the CPRD study time period, their large size means
they include multiple NHS trusts and many GP practices, which
may vary in their arrangements for adults with ADHD. The size
of defined regions also made it difficult to incorporate geographic
deprivation measures into the analysis, as deprivation varies at
much smaller geographies than this. Future research would
benefit from using smaller geographic areas.
Finally, our sample frame was young adults with a childhood
diagnosis of ADHD. Another important gap in adult services for
ADHD is assessment, diagnosis and treatment for those who
present as adults for the first time. Given our sample frame, we
cannot comment on this important aspect of access to services,
which should be addressed using an alternative sample frame. It
would be interesting to see if regional variation in this related
group of patients followed a similar regional pattern.
Implications
In conclusion, these findings, combined with evidence that more
than one in ten commissioners are failing to meet expected
Mental Health Investment Standards, point to unequal provision
of resources for mental health.28 Large and unchanging regional
health inequalities in England point to the need for targeted inter-
ventions to improve the equity of access to care more generally.29
Studies of variation can help to increase accountability for mental
health service provision, and indexing regional differences in pre-
scribing and referral rates is one way of highlighting inequity.
This data can contribute to planning regional service development
and provision and, ultimately, to addressing health inequalities in
people with ADHD.
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